The impact of antihypertensives on kidney disease

Area of Science:

• Nephrology
• Cardiology
• Internal Medicine

Background:

• Arterial hypertension and chronic kidney disease (CKD) share a strong bidirectional relationship.
• Elevated blood pressure (BP) significantly increases cardiovascular (CV) risk in CKD patients.
• Effective BP management is essential for renal protection and mitigating CV complications.

Purpose of the Study:

• To review current recommendations for blood pressure control in patients with chronic kidney disease.
• To discuss the safety and efficacy of strict BP control, including recent findings from the SPRINT trial.
• To outline current therapeutic strategies and the need for novel pharmacological approaches in managing hypertension in CKD.

Main Methods:

• Review of current clinical guidelines and landmark trials (e.g., SPRINT) concerning hypertension management in CKD.
• Analysis of treatment strategies, including combination therapy with ARBs or ACEi, calcium channel blockers, and diuretics.
• Evaluation of emerging therapeutic options and their potential impact on BP control in CKD.

Main Results:

• Current guidelines recommend BP <140/90 mmHg for CKD patients, with stricter targets (<130/80 mmHg) often advised if albuminuria is present.
• The SPRINT trial suggests that strict BP control to systolic BP around 120 mmHg is safe in CKD, though further validation is required.
• Standard treatment typically involves combination therapy, often initiated with an ARB or ACEi.

Conclusions:

• Optimizing blood pressure control is paramount in managing chronic kidney disease and reducing associated cardiovascular risks.
• While current guidelines provide targets, ongoing research, including the implications of the SPRINT trial, may refine these recommendations.
• The development of new antihypertensive medications and the exploration of novel therapeutic classes, such as certain oral anti-diabetic drugs, hold promise for improved CKD management.